SLC5A2 and sarcopenia: Additionally, the number of patients in the SGLT2-inhibitors-used group was small; thus, analyses to match patient backgrounds between the two groups, such as propensity matching, were difficult to perform and so was subgroup analyses in patients with sarcopenia or frailty.